# Study of Patupilone in Prostate Cancer Patients Who Progress After Hormone Therapy and Docetaxel Chemotherapy

> **NCT00407251** · PHASE2 · COMPLETED · sponsor: **British Columbia Cancer Agency** · enrollment: 73 (estimated)

## Conditions studied

- Hormone Refractory Prostate Cancer

## Interventions

- **DRUG:** Patupilone

## Key facts

- **NCT ID:** NCT00407251
- **Lead sponsor:** British Columbia Cancer Agency
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-02
- **Primary completion:** 2010-06
- **Final completion:** —
- **Target enrollment:** 73 (ESTIMATED)
- **Last updated:** 2010-11-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00407251

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00407251, "Study of Patupilone in Prostate Cancer Patients Who Progress After Hormone Therapy and Docetaxel Chemotherapy". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00407251. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*